Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index; 25 of the 88 sources its claims cite were checked for support.

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

Open access
McManus, Hannah D., Dorff, Tanya, Morgans, Alicia K., Sartor, Oliver, Shore, Neal, Armstrong, Andrew J. · 2025 · Prostate Cancer and Prostatic Diseases

Abstract

Novel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent lines of therapy. We conducted a comprehensive review of published evidence from pivotal clinical trials and recent guidelines for the treatment of mCRPC. We further identify gaps in knowledge and areas for future research. Key considerations to help guide treatment selection for patients with mCRPC include personal treatment history, individual clinical characteristics, symptoms, prognosis, availability of clinical trials, and other patient-specific factors. Genetic testing and prostate-specific membrane antigen-targeted imaging are important tools to evaluate candidacy for newer therapeutic options such as poly (ADP-ribose) polymerase inhibitors, alone or in combination with androgen receptor pathway inhibitors, and [ 177 Lu]Lu-PSMA-617. This article provides an overview of the evolving treatment landscape of mCRPC, discussing guideline-recommended treatment options and data from key clinical trials, while highlighting ongoing trials that may impact the future treatment landscape. Recommendations for optimal treatment sequencing based on individual patient factors are provided.

Overview

CoChat Summary

## TL;DR

This is a narrative review of how to sequence treatments for metastatic castration-resistant prostate cancer (mCRPC), emphasizing individualized decisions based on prior therapy, disease features, genomics, imaging, symptoms, and access. It highlights newer options such as PARP inhibitors and PSMA-targeted radioligand therapy, while noting that optimal sequencing remains uncertain.

## Key findings

  • Treatment selection for mCRPC should be individualized using prior treatment history, disease characteristics, prognosis, symptoms, patient preferences, and clinic-level factors.
  • Genetic testing is positioned as central to treatment choice: the paper states NCCN v4.2024 recommends both germline and somatic tumor testing for all patients with metastatic PC, yet only 13% (674/5213) of patients with mCRPC had any genetic testing in a 2013–2019 study.
  • For PSMA-positive disease, the paper cites VISION showing [177Lu]Lu-PSMA-617 plus best SOC prolonged rPFS and OS, and TheraP showing fewer grade ≥3 adverse events, improved patient-reported outcomes, and similar OS versus cabazitaxel.
  • For PARP inhibitor/ARPI combinations in first-line mCRPC, the paper reports trial results including:
  • PROpel: median PFS 24.8 vs 16.6 months; HR 0.66; final OS 42.1 vs 34.7 months.
  • TALAPRO-2: rPFS not reached vs 21.9 months; HR 0.63.
  • MAGNITUDE: HRRm cohort median rPFS 16.5 vs 13.7 months; HR 0.73; no benefit in the non-HRRm cohort (HR 1.09).
  • The review states there is benefit in some biomarker-defined subgroups, but also that patients with prior ARPI resistance were not represented in several pivotal PARP inhibitor combination trials, so benefit in that setting is unknown.

## Methods

  • Narrative comprehensive review of published evidence from pivotal clinical trials and recent guidelines for mCRPC.
  • Sources included guideline documents and key trial reports; no new patient cohort, intervention, or original dataset is described.
  • The main analysis is qualitative synthesis to identify treatment-sequencing principles, evidence gaps, and future research directions.

## Limitations

  • The paper explicitly states it focuses on practice patterns in the US, and says further work describing different treatment sequences globally is needed.
  • The text makes evident that it is not a systematic review or meta-analysis; it synthesizes evidence narratively rather than using a formal search and selection framework.
  • Many recommendations are based on trials that may not match current real-world sequencing: the paper notes pivotal studies often included patients who had not received prior ARPI, and often relied on conventional imaging rather than current PSMA PET.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41391-024-00906-z

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Considerations during treatment selection for patients with mCRPC*. CT computed tomography, mCRPC metastatic castration-resistant prostate cancer, PET positron emission tomography, PSMA prostate-specific membrane antigen. *Please note that not all factors presented in this figure were within the scope of this review.
Fig. 1 Considerations during treatment selection for patients with mCRPC*. CT computed tomography, mCRPC metastatic castration-resistant prostate cancer, PET positron emission tomography, PSMA prostate-specific membrane antigen. *Please note that not all factors presented in this figure were within the scope of this review.CC BY-NC-ND · PubMed Central
Fig. 2 Treatment selection algorithms for mCRPC. A Treatment selection algorithm for mCRPC in patients with progressive disease following treatment with an ARPI. B Treatment selection algorithm for mCRPC in patients without prior ARPI. ADT androgen deprivation therapy, ARPI androgen receptor pathway inhibitor, CRPC castration-resistant prostate cancer, CT computed tomography, HRR homologous recombination repair, Lu lutetium, mCRPC metastatic castration-resistant prostate cancer, MSI-H microsatellite instability-high, PARP poly (ADP-ribose) polymerase, PET positron emission tomography, PSMA prostate-specific membrane antigen, TMB tumor mutational burden. *If aggressive mCRPC disease features (e.g., liver metastases, short time to CRPC, multiple lytic bone lesions), prioritize taxane chemotherapy (consider adding carboplatin) if a candidate.
Fig. 2 Treatment selection algorithms for mCRPC. A Treatment selection algorithm for mCRPC in patients with progressive disease following treatment with an ARPI. B Treatment selection algorithm for mCRPC in patients without prior ARPI. ADT androgen deprivation therapy, ARPI androgen receptor pathway inhibitor, CRPC castration-resistant prostate cancer, CT computed tomography, HRR homologous recombination repair, Lu lutetium, mCRPC metastatic castration-resistant prostate cancer, MSI-H microsatellite instability-high, PARP poly (ADP-ribose) polymerase, PET positron emission tomography, PSMA prostate-specific membrane antigen, TMB tumor mutational burden. *If aggressive mCRPC disease features (e.g., liver metastases, short time to CRPC, multiple lytic bone lesions), prioritize taxane chemotherapy (consider adding carboplatin) if a candidate.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

17 Valid · 0 Not valid · 35 Not checked · 4 Own results and interpretations

23 more claims · 7 with their cited sources checked

Create a free account to see all 56 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Citations

Cites

Show all 77 references

Research works printed but not linked: 4

  1. AstraZeneca: Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer. 2023. https://www.astrazeneca.com/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer.html.
  2. Novartis Pharmaceuticals Corporation: Press Release. Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting. 2023. https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting.
  3. UroToday: Press Release. ASCO 2024: PSMAfore: HRQoL and pain in a phase 3 study of 177Lu-PSMA-617 in taxane-naïve patients with mCRPC. 2024. https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer/152475-asco-2024-psmafore-hrqol-and-pain-in-a-phase-3-study-of-177lu-psma-617-in-taxane-naive-patients-with-mcrpc.html.
  4. Exelixis I: Press Release. Exelixis and Ipsen announce positive results from phase 3 CONTACT-02 pivotal trial evaluating cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer. 2023. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-ipsen-announce-positive-results-phase-3-contact-02.

Cited by

See all 32

Metadata

Authors
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J.
Affiliations
  • Duke University (US)
  • City Of Hope National Medical Center (US)
  • Dana-Farber Cancer Institute (US)
  • Mayo Clinic (US)
  • Carolina Urologic Research Center (US)
Corresponding author
Armstrong, Andrew J.
Venue
Prostate Cancer and Prostatic Diseases
Published
2024-10-17
Volume
28
Issue
3
Pages
672-683
ISSN
  • 1365-7852 (ISSN-L)
  • 1476-5608
OpenAlex
W4403510167
Cited by
32
References
77
Citations by year
2026: 21 · 2025: 11
FWCI
2.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Prostate Cancer and Prostatic Diseases (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novartis Pharmaceuticals Corporation (N/A)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
metastatic castration-resistant prostate cancer, treatment sequencing, second-line therapy, PARP inhibitors, androgen receptor pathway inhibitors, 177Lu-PSMA-617, genetic testing, treatment selection, inclusion and exclusion criteria, treatment landscape
MeSH terms
Humans, Male, Neoplasm Metastasis, Prognosis, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. https://app.cochat.ai/papers/10.1038/s41391-024-00906-z
The paper
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025). Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00906-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.